Book a Meeting

Non-Fucosylated Anti-Human CD39 (BY40) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-664ZP) Datasheet

Target
CD39
Isotype
Mouse IgG
Description
ADCC-Enhanced anti-CD39 (BY40) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform. By reducing the fucosylation of the Fc region, the ADCC-enhanced antibody shows an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Cancer
Classification
Therapeutic antibody; biobetter
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD39
Full Name
ectonucleoside triphosphate diphosphohydrolase 1
Background
CD38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling.
Alternative Names
ENTPD1; ectonucleoside triphosphate diphosphohydrolase 1; CD39; SPG64; ATPDase; NTPDase-1; NTPDase 1; CD39 antigen; ecto-apyrase; ecto-ATPase 1; ecto-ATPDase 1; ecto-ATP diphosphohydrolase 1; lymphoid cell activation antigen
Gene ID
UniProt ID
Cellular Localization
Extracellular region or secreted, Endoplasmic reticulum
HGNC
OMIM
Involvement in Disease
Diseases associated with ENTPD1 include Spastic Paraplegia 64, Autosomal Recessive and Paraplegia.
Related Pathways
Its related pathways are ATP/ITP metabolism and Metabolism of nucleotides.
Function
In the nervous system, it can hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. It is also possible to prevent platelet aggregation by hydrolyzing platelet-activated ADP. Hydrolysis of ATP and ADP have the same effect.
Post-translational modifications
The N-terminus is blocked. Palmitoylated in the N-terminal part.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Mouse IgG
Antibody Clone
BY40
Host
Mouse
Species Reactivity
Human
Description
The antibody against human CD39 can be used for the treatment or prevention of cancers and infectious diseases.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK